| Texto: |
Prezados, boa tarde.
Estes são os grupos e os respectivos artigos para serem apresentados no nosso encontro do dia 25.
Abraços.
| Grupos |
Artigo |
Data |
| Brenda, Priscila e Verônica |
Wang, Q., Jiang, C., Zheng, X., Zhu, X., Yan, S., Wang, H., Fu, R., Fan, H., & Chen, Y. (2017). Insight into the pharmacokinetic behavior of tanshinone IIA in the treatment of Crohn's disease: comparative data for tanshinone IIA and its two glucuronidated metabolites in normal and recurrent colitis models after oral administration. Xenobiotica; the fate of foreign compounds in biological systems, 47(1), 66–76. https://doi.org/10.3109/00498254.2016.1160158 |
25/mai |
| Lubna e Maria do Perpétuo Socorro |
Rubino, C. M., Polak, M., Schröpf, S., Münch, H. G., Smits, A., Cossey, V., Tomasik, T., Kwinta, P., Snariene, R., Liubsys, A., Gardovska, D., Hornik, C. D., Bosheva, M., Ruehle, C., Litherland, K., & Hamed, K. (2021). Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients. The Pediatric infectious disease journal, 40(11), 997–1003. https://doi.org/10.1097/INF.0000000000003296 |
25/mai |
| Thalyne, Talissa e Thallytta |
Reich, D. S., Arnold, D. L., Vermersch, P., Bar-Or, A., Fox, R. J., Matta, A., Turner, T., Wallström, E., Zhang, X., Mareš, M., Khabirov, F. A., Traboulsee, A., & Tolebrutinib Phase 2b Study Group (2021). Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. The Lancet. Neurology, 20(9), 729–738. https://doi.org/10.1016/S1474-4422(21)00237-4 |
25/mai |
|
